Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia-Reference-Cited by-同舟云学术

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Published:2018-05-08 Issue:5 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Fortin Patricia M¹,Fisher Sheila A²,Madgwick Karen V³,Trivella Marialena⁴,Hopewell Sally⁵,Doree Carolyn²,Estcourt Lise J⁶

Affiliation:

1. 5639 Gowland Rd. Sechelt BC Canada V0N 3A8

2. NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ

3. North Middlesex University Hospital NHS Trust; Department of Pathology; Sterling Way London UK N18 1QX

4. University of Oxford; Centre for Statistics in Medicine; Botnar Research Centre Windmill Road Oxford UK OX3 7LD

5. University of Oxford; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS); Botnar Research Centre, Windmill Road Oxford Oxfordshire UK OX3 7LD

6. NHS Blood and Transplant; Haematology/Transfusion Medicine; Level 2, John Radcliffe Hospital Headington Oxford UK OX3 9BQ

Publisher

Wiley

Subject

Pharmacology (medical)

Reference134 articles.

1. A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major;Aydinok;Blood,2006

2. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major;Aydinok;Haematologica,2007

3. A randomized controlled prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine with L1 and DFO monotherapy in patients with thalassemia major;Manz;Haematologica,2006

4. Badawy S Hassan TH Hesham MA Badr MA Evaluation of iron chelation therapy in B-thalassemic patients in Zagazig University Hospital ASPHO abstracts (The American Society of Pediatric Hematology/Oncology) 2010 799 800

5. Clinical pharmacist-provided services in iron overloaded Beta-thalassemia major children; A new insight to patient care;Bahnasawy;Basic & Clinical Pharmacology & Toxicology,2017

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of CENPF and NDC80 in the rehabilitation nursing of hepatocellular carcinoma and cirrhosis: An observational study;Medicine;2024-05-03

2. Compare the Efficacy and Safety of Deferoxamine, Deferasirox, and Deferiprone in Patients With Sickle Cell Disease or Transfusion-Dependent Anemia: A Network Meta-Analysis of Randomized Control Trials;Cureus;2024-02-05

3. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial;BMJ Open;2024-02

4. Ferroptosis as an emerging target in sickle cell disease;Current Research in Toxicology;2024

5. Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial;PLOS ONE;2023-12-27